Inhaled Treprostinil for PAH: Open-label Extension

• Status: Withdrawn
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Open-label extension of RIN-PH-302.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: United Therapeutics
• Treatments: Treprostinil

Criteria

Participation and completion of all required visits for study RIN-PH-302.